Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real‐world setting in Japan are limited. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.